Miglitol: A review of its therapeutic potential in type 2 diabetes mellitus

Drugs

Volumn 59, Issue 3, 2000, Pages 521-549

  Scott, Lesley J ^a   Spencer, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; AMYLASE; BIGUANIDE; CARBOHYDRATE; CHOLESTEROL; GASTRIC INHIBITORY POLYPEPTIDE; GLIBENCLAMIDE; GLUCOSE; INSULIN; METFORMIN; MIGLITOL; ORAL ANTIDIABETIC AGENT; PHENYTOIN; PROPRANOLOL; RANITIDINE; SULFONYLUREA; TYROSINE; WARFARIN;

ABDOMINAL PAIN; CARBOHYDRATE METABOLISM; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIARRHEA; DIET RESTRICTION; DOSE RESPONSE; DRUG ABSORPTION; DRUG ANTAGONISM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG INHIBITION; DRUG TOLERABILITY; FLATULENCE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW;

EID: 0034006999     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059030-00012     Document Type: Review

References (99)

1. 1. Zimmerman BR, Espenshade J, Fujimoto WY, et al.The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1996 Jan; 19 Suppl. 1: 54-61
2. 2. Mandrup-PoulsenT. Diabetes. BMJ 1998 Apr 18; 316: 1221-5
3. 3. Williams G. Management of non-insulin-dependent diabetes mellitus. Lancet 1994; 343 (8889): 95-100
4. 4. Gaster B, Hirsch IB. The effects of improved glycemic control on complications in type 2 diabetes. Arch Intern Med 1998 Jan 26; 158: 134-40
5. 5. Scheen AJ, Lefebvre PJ. Antihyperglycaemic agents: drug interactions of clinical importance. Drug Saf 1995 Jan; 12: 32-45
6. 6. Mahler RJ, Adler ML. Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab 1999 Apr; 84: 1165-71
7. 7. Johnston PS, Feig PU, Coniff RF, et al. Chronic treatment of African-American type 2 diabetic patients with α-glucosidase inhibition. Diabetes Care 1998 Mar; 21: 416-22
8. 8. Henry RR. Glucose control and insulin resistance in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996 Jan 1; 124 (Part 2): 97-103
9. 9. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998 Oct; 41: 1241-8
10. 10. Hollander PA. New oral agents for type II diabetes: taking a more aggressive approach to therapy. Postgrad Med 1995 Dec; 98: 110-26
11. 11. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65
12. 12. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86
13. 13. Monnier L. The role of blood-glucose lowering agents in the light of the UKPDS. Diabetes Obesity Metab 1999; 1 Suppl. 2: 14-23
14. 14. Baron AD. Postprandial hyperglycaemia and α-glucosidase inhibitors. Diabetes Res Clin Pract 1998; 40 Suppl.: 51-5
15. 15. Standl E. Cardiovascular risk in type 2 diabetes. Diabetes Obesity Metab 1999; 1 Suppl. 2: 24-36
16. 16. Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycaemia. Drugs 1999 Jan; 57: 19-29
17. 17. Lefebvre PJ, Scheen AJ. The postprandial state and risk of cardiovascular disease. Diabet Med 1998; 15 Suppl. 4: 63-8
18. 18. Haffner SM. The importance of hyperglycaemia in the nonfasting state to the development of cardiovascular disease. Endocr Rev 1998; 19: 583-92
19. 19. Savage PJ. Cardiovascular complications of diabetes mellitus: what we know and what we need to know about their prevention. Ann Intern Med 1996; 124 (Pt 2): 123-6
20. 20. Colwell JA. Pharmacological strategies to prevent macrovascular disease in NIDDM. Diabetes 1997 Sep; 46 Suppl. 2: 131-4
21. 21. Wagenknecht LE, Mayer EJ, Rewers M, et al. The Insulin Resistance Atherosclerosis Study (IRAS ): objectives, design, and recruitment results. Ann Epidemiol 1995 Nov; 5: 464-72
22. 22. Pyörälä K, Steiner G. Will correction of dyslipoproteinaemia reduce coronary heart disease risk in patients with non-insulin-dependent diabetes ? Need for trial evidence. Ann Med 1996 Aug; 28: 357-62
23. 23. Fontbonne A, Eschwège E, Cambien F, et al. Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Diabetologia 1989; 32: 300-4
24. 24. Colwell JA. Intensive insulin therapy in type II diabetes: rationale and collaborative clinical trial results. Diabetes 1996 Jul; 45 Suppl. 3: 87-90
25. 25. Bischoff H. Pharmacology of α-glucosidase inhibition. Eur J Clin Invest Suppl. 1994; 24 (3): 3-10
26. 26. Lefebvre PJ, Scheen AJ. Management of non-insulin-dependent diabetes mellitus. Drugs 1992; 44 Suppl. 3: 29-38
27. 27. Balfour JA, Clissold SP. Management of non-insulin-dependent diabetes mellitus: defining the role of metformin. Dis Manage Health Outcomes 1997 Jan; 1: 49-59
28. 28. Salvatore T, Giugliano D. Pharmacokinetic-pharmacodynamic relationships of acarbose. Clin Pharmacokinet 1996 Feb; 30: 94-106
29. 29. Feld S. American Association of Clinical Endocrinologists Diabetes Guidelines. Endocr Pract 1999; 6 (1): 3-27
30. 30. Clissold SP, Edwards C. Acarbose: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1988; 35: 214-43
31. 31. Balfour JA, McTavish D. Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993 Dec; 46: 1025-54
32. 32. Donckier J, Williams G. The roles of α-glucosidase inhibitors in diabetes. Eur J Clin Invest 1994 Aug; 24: 522-4
33. 33. Lembcke B, Folsch UR, Creutzfeldt W. Effect of 1-desoxynojirimycin derivatives on small intestinal disaccharidase activities and on active transport in vitro. Digestion 1985; 31: 120-7
34. 34. Samulitis BK, Goda T, Lee SM, et al. Inhibitory mechanism of acarbose and 1-deoxynojirimycin derivatives on carbohydrases in rat small intestine. Drugs Exp Clin Res 1987; 13: 517-24
35. 35. Lembcke B, editor. Therapy principle of absorption delay: the effect principle of α-glucosidase inhibition. Berlin: Springer-Verlag, 1991
36. 36. Wisselaar HA, van-Dongen JM, Reuser AJ. Effects of N-hydroxyethyl-1-deoxynojirimycin (BAY m 1099) on the activity of neutral-and acid α-glucosidases in human fibroblasts and HepG2 cells. Clin Chim Acta 1989 Jun 15; 182: 41-52
37. 37. Reuser AJJ, Wisselaar HA. An evaluation of the potential side-effects of α-glucosidase inhibitors used for the management of diabetes mellitus. Eur J Clin Invest 1994 Aug; 24 Suppl. 3: 19-24
38. 38. Ludolph D, Gross V, Katz NR, et al. Effect of the α-glucosidase inhibitor N-hydroxyethyl-1-deoxynojirimycin (Bay m 1099) on the biosynthesis of liver secretory glycoproteins. Biochem Pharmacol 1989 Aug 1; 38: 2479-86
39. 39. Ladas SD, Frydas A, Papadopoulos A, et al. Effects of α-glucosidase inhibitors on mouth to caecum transit time in humans. Gut 1992 Sep; 33: 1246-8
40. 40. Taylor RH, Barker HM, Bowey EA, et al. Regulation of the absorption of dietary carbohydrate in man by two new glycosidase inhibitors. Gut 1986 Dec; 27: 1471-8
41. 41. Holt PR, Thea D, Yang M-Y, et al. Intestinal and metabolic responses to an α-glucosidase inhibitor in normal volunteers. Metabolism 1988 Dec; 37; 1163-70
42. 42. Heinz G, Komjati M, Korn A, et al. Reduction of postprandial blood glucose by the α-glucosidase inhibitor Miglitol (BAY m 1099) in type II diabetes. Eur J Clin Pharmacol 1989; 37: 33-6
43. 43. Joubert PH, Bam WJ, Manyane N. Effect of an α-glucosidase inhibitor (BAY m 1099) on post-prandial blood glucose and insulin in type II diabetics. Eur J Clin Pharmacol 1986; 30: 253-5
44. 44. Katsilambros N, Philippides P, Toskas A, et al. A double-blind study on the efficacy and tolerance of a new α-glucosidase inhibitor in type-2 diabetics. Arzneimittelforschung 1986 Jul; 36: 1136-8
45. 45. Kingma PJ, Menheere PPCA, Sels JP, et al. α-Glucosidase inhibition by miglitol in NIDDM patients. Diabetes Care 1992 Apr; 15: 478-83
46. 46. Scott AR, Tattersall RB. α-Glucosidase inhibition in the treatment of non-insulin-dependent diabetes mellitus. Diabetic Med 1988 Jan; 5: 42-6
47. 47. Samad AH, Ty-Willing TS, Alberti KGMM, et al. Effects of BAY m 1099, new α-glucosidase inhibitor, on acute metabolic responses and metabolic control in NIDDM over 1 mo. Diabetes Care 1988 Apr; 11: 337-44
48. 48. Schnack C, Piager RJF, Winkler J, et al. Effects of 8-wk α-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output, and peripheral insulin sensitivity in poorly controlled type II diabetic patients. Diabetes Care 1989 Sep; 12: 537-43
49. 49. Johnson AB, Taylor R. Does suppression of postprandial blood glucose excursions by the α-glucosidase inhibitor miglitol improve insulin sensitivity in diet-treated type II diabetic patients? Diabetes Care 1996 Jun; 19: 559-63
50. 50. Joubert PH, Foukaridis GN, Bopape ML. Miglitol may have a blood glucose lowering effect unrelated to inhibition of α-glucosidase. Eur J Clin Pharmacol 1987; 31: 723-4
51. 51. Joubert PH, Venter HL, Foukaridis GN. The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism? Br J Clin Pharmacol 1990 Sep; 30: 391-6
52. 52. Sels JPJE, Nauta JJP, Menheere PPCA, et al. Miglitol (Bay m 1099) has no extraintestinal effects on glucose control in healthy volunteers. Br J Clin Pharmacol 1996 Oct; 42: 503-6
53. 53. Lembcke B, Fölsch UR, Gatzemeier W, et al. Inhibition of glycemic and hormonal responses after repetitive sucrose and starch loads by different doses of the α-glucosidase inhibitor miglitol (BAY m 1099) in man. Pharmacology 1991 Dec; 43: 318-28
54. 54. Lembcke B, Diederich M, Fölsch UR, et al. Postprandial glycemic control, hormonal effects and carbohydrate malabsorption during long-term administration of the α-glucosidase inhibitor miglitol. Digestion 1990 Sep; 47: 47-55
55. 55. Requejo F, Uttenthal LO, Bloom SR. Effects of α-glucosidase inhibition and viscous fibre on diabetic control and postprandial gut hormone responses. Diabetic Med 1990 Jul; 7: 515-20
56. 56. Lembcke B, Lamberts R, Wöhler J, et al. Lysosomal storage of glycogen as a sequel of α-glucosidase inhibition by the absorbed deoxynojirimycin derivative emiglitate (BAY o 1248). A drug-induced pattern of hepatic glycogen storage mimicking Pompe's disease (glycogenosis type II) [in German]. Res Exp Med Berl 1991; 191: 389-404
57. 57. Hillebrand I, Boehme K, Graefe KH, et al. The effect of new α-glucosidase inhibitors (BAY m 1099 and BAY o 1248) on meal-stimulated increases in glucose and insulin levels in man. Klin Wochenschr 1986 Apr 15; 64: 393-6
58. 58. Karam JH, Salber PR, Forsham PH. Pancreatic hormones and diabetes mellitus. In: Greenspan FS, editor. Basic and clinical endocrinology. 3rd ed. Morwalk (CT): Apple & Lange, 1991: 592-650
59. 59. Mathur S, Fonseca V, Dandona P. The effect of the α-glucosidase inhibitor miglitol on insulin sensitivity in non-insulin dependent diabetics [abstract]. Diabetes 1991 May; 40 Suppl. 1: 336
60. 60. Arends J, Willms BH. Smoothing effect of a new α-glucosidase inhibitor BAY m 1099 on blood glucose profiles of sulfonylurea-treated type II diabetic patients. Horm Metah Res 1986 Nov; 18: 761-4
61. 61. Ahr H-J, Boberg M, Brendel E, et al. Pharmacokinetics of miglitol: absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Arzneimittelforschung 1997 Jun; 47: 734-45
62. 62. Beneke PC, Müller FO, Van Dyk M, et al. The pharmacokinetics of miglitol over a therapeutic dose range [abstract]. S Afr Med J 1991 Dec 7; 80: 622
63. 63. Sanofi-Synthelabo. Diastabol: product monograph. Paris, France
64. 64. Johnston PS, Coniff RF, Hoogwerf BJ, et al. Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care 1994 Jan; 17: 20-9
65. 65. Segal P, Feig PU, Schernthaner G, et al. The efficacy and safety of miglitol therapy compared with glibenclamide in patients with NIDDM inadequately controlled by diet alone. Diabetes Care 1997 May; 20: 687-91
66. 66. Bayer Vital GmbH and Company K.G. Multicentre, multinational, double-blind, placebo-controlled clinical study to investigate the efficacy and tolerability of miglitol (Bay m 1099) in type 2 diabetes unsatisfactorily treated with sulphonylurea and metformin. Bayer Vital GmbH and Company K.G. (Germany), 1997. Report no.: PH 26828 (Data on file)
67. 67. Bayer Vital GmbH and Company K.G. A multicentre, double-blind, placebo-controlled study, investigating the efficacy and safety of miglitol in combination with metformin as compared to metformin monotherapy in the treatment of patients with non-insulin-dependent diabetes mellitus (type II) inadequately controlled with diet alone. Bayer Vital GmbH and Company K.G (Germany), 1997. Report no.:MMRR-1439 (Data on file)
68. 68. Bayer Corporation. International multicentre, double-blind, placebo-controlled clinical study to investigate the efficacy and tolerability of miglitol (Bay m 1099) in type 2 diabetics unsatisfactorily treated with metformin. Bayer Corporation (Germany), 1998. Report no. PH-2827/1 (Data on file)
69. 69. Salvatore T, Scheen AJ, Ferreira Alves de Magalhaes AC, et al. Slight modifications of the pharmacokinetic parameters of glibenclamide after treatment with the α-glucosidase inhibitor miglitol in normal subjects [abstract]. Therapie 1990 Jul-Aug; 45: 365
70. 70. Schall R, Müller FO, Hundt HKL, et al. Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males. Arzneimittelforschung 1996 Jan; 46: 41-6
71. 71. Richardt D, Rosmarin C, Havlik I, et al. No effect of miglitol on the oral bioavailability of single-dose phenytoin in healthy males. Clin Drug Invest 1997 Mar; 13: 171-4
72. 72. Mosby, Miglitol; prescribing information. In: Rabbitt KE, editor. Mosby's GenRx. 9th ed. Missouri: Mosby, Inc., 1999: 1506-8
73. 73. Standl E, Schernthaner G, Rybka J, et al. Improved glycaemic control with miglitol in type 2 diabetics insufficiently controlled on oral hypoglycaemics [abstract and poster no.839]. Diabetologia 1999; 42 Suppl. 1: 223
74. 74. Drent ML. Miglitol as single oral hypoglycemic agent in type 2 diabetes [abstract]. Diabetologia 1994; 37 Suppl. 1: 211
75. 75. Rybka J, Goke B, Sissmann J. European comparative study of 2 α-glucosidase inhibitors, miglitol and acarbose [abstract]. Diabetes 1999 May; 48 Suppl. 1: 101
76. 76. Pagano G, Marena S, Corgiat-Mansin L, et al. Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients [French]. Diabete Metab 1995 Jun; 21: 162-7
77. 77. Johnston PS, Lebovitz HE, Coniff RF, et al. Advantages of α-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients. J Clin Endocrinol Metab 1998 May; 83: 1515-22
78. 78. Johnston PS, Feig PU, Coniff RF, et al. Long-term titrated-dose α-glucosidase inhibition in non-insulin-requiring Hispanic NIDDM patients. Diabetes Care 1998 Mar; 21: 409-15
79. 79. Coniff RF, Johnston PS, Krol A. Long-term effects of the α-glucosidase inhibitor miglitol (BAY m 1099) in NIDDM patients treated with maximal-dose sulfonylurea [abstract]. Diabetes 1996 May; 45 Suppl. 2: 221
80. 80. Maislos M, Van Gaal L, Segal P. Miglitol in combination with metformin improves glycaemic control in type 2 diabetics [abstract and poster no. 838]. Diabetologia 1999; 42 Suppl. 1: 223
81. 81. Mitrakou A, Tountas N, Raptis AE, et al. Long-term effectiveness of a new α-glucosidase inhibitor (BAY m 1099-miglitol) in insulin-treated type 2 diabetes mellitus. Diabetic Med 1998 Aug; 15: 657-60
82. 82. Jay RH, Round JM, Betteridge DJ. Effects of miglitol on glucose control, intermediary metabolism, lipoproteins and clotting factors in type 1 diabetes [abstract]. Diabetic Med 1992 Jul; 9 Suppl. 1: 51A
83. 83. Dolben J, Luzio S, Smith H, et al. Miglitol: a new α-glucosidase inhibitor decreases post-prandial glucose excursions [abstract]. Br J Clin Pharmacol 1992 Feb; 33: 225P
84. 84. Bayer Vital GmbH and Company K.G. Efficacy and tolerability of miglitol (Bay m 1099) and acarbose (Bay g 5421) in type II diabetes. Bayer Vital GmbH and Company K.G. (Germany), 1994. Report no.: R6245. (Data on file)
85. 85. United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-58
86. 86. Bayer AG. A multi-centre, double-blind, placebo-controlled group comparsion study to investigate the efficacy, tolerability and safety of miglitol (Bay m 1099) in three different doses in the treatment of patients with non-insulin dependent diadebtes mellitus (NIDDM) inadequately controlled with maximum daily doses of sulphonylurea and diet. Bayer Corporation (Germany), 1995. Report no. 1313 (Data on file)
87. 87. Evans J, Krentz AJ. Recent developments and emerging therapies for type 2 diabetes mellitus. Drugs Res Dev 1999; 2 (2): 75-94
88. 88. Scheen AJ. Drug treatment of non-insulin-dependent diabetes mellitus in the 1990s: achievements and future developments. Drugs 1997 Sep; 54: 355-68
89. 89. Zimmerman BR. Preventing long term complications. Implications for combination therapy with acarbose. Drugs 1992; 44 Suppl. 3: 54-9
90. 90. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
91. 91. Kuusisto J, Mykkänen L, Pyörälä K, et al. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43: 960-7
92. 92. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39: 1577-83
93. 93. Tominaga M, Eguchi H, Manaka H, et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Fungata Diabetes Study. Diabetes Care 1999; 22 (6): 920-4
94. 94. Rabasa-Lhoret R, Chiasson JL. Potential of α-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance. Drugs Aging 1998 Aug; 13: 131-43
95. 95. Bressler R, Johnson DG. Oral antidiabetic drug use in the elderly. Drugs Aging 1996 Dec; 9: 418-37
96. 96. Lardinois CK. Type 2 diabetes: glycemic targets and oral therapies for older patients. Geriatrics 1998 Nov; 53 (11): 22-3, 27-8, 33-4, 37-9
97. 97. Bretzel RG. The United Kingdom Prospective Study (UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 1998; 106: 369-72
98. 98. Mooradian AD. Drug therapy of non-insulin-dependent diabetes mellitus in the elderly. Drugs 1996 Jun; 51: 931-41
99. 99. Lunt H. Diabetes mellitus in older patients: is tight blood glucose control warranted? Drugs Aging 1996 Jun; 8: 401-7